NQTrp

• UNSPSC Description:

  NQTrp, an aromatic naphthoquinone-tryptophan hybrid molecule, an inhibitor of the aggregation of the tau protein with generic anti-amyloidogenic effects. NQTrp inhibits the in vitro aggregation of hexapeptide (41GCWMLY46 within the N-terminus of γD-crystallin) as well as full-length γD-crystallin[1].

• Target Antigen:

  Tau Protein

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/nqtrp.html

• Purity:

  98.37

• Solubility:

  DMSO : 125 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(O)[C@H](CC1=CNC2=CC=CC=C12)NC(C3=O)=CC(C4=C3C=CC=C4)=O

• Molecular Weight:

  360.36

• References & Citations:

  [1]Malak Abu-Hussien, et al. An amyloidogenic hexapeptide from the cataract-associated γD-crystallin is a model for the full-length protein and is inhibited by naphthoquinone-tryptophan hybrids. Int J Biol Macromol. 2020 Aug 15;157:424-433.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light)

• Clinical Information:

  No Development Reported

• CAS Number:

  185351-19-3